Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | LINC00342 | Human | acrylamide | decreases expression | EXP | | 6480464 | Acrylamide results in decreased expression of LINC00342 mRNA | CTD | PMID:32763439 | LINC00342 | Human | aristolochic acid A | decreases expression | EXP | | 6480464 | aristolochic acid I results in decreased expression of LINC00342 mRNA | CTD | PMID:33212167 | LINC00342 | Human | beta-lapachone | decreases expression | EXP | | 6480464 | beta-lapachone results in decreased expression of LINC00342 mRNA | CTD | PMID:38218311 | LINC00342 | Human | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of LINC00342 mRNA | CTD | PMID:36232920 | LINC00342 | Human | butanal | decreases expression | EXP | | 6480464 | butyraldehyde results in decreased expression of LINC00342 mRNA | CTD | PMID:26079696 | LINC00342 | Human | cadmium dichloride | increases expression | EXP | | 6480464 | Cadmium Chloride results in increased expression of LINC00342 mRNA | CTD | PMID:38382870 and PMID:38568856 | LINC00342 | Human | dorsomorphin | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00342 mRNA | CTD | PMID:27188386 | LINC00342 | Human | methylisothiazolinone | decreases expression | EXP | | 6480464 | 2-methyl-4-isothiazolin-3-one results in decreased expression of LINC00342 mRNA | CTD | PMID:31629900 | LINC00342 | Human | methylmercury chloride | increases expression | EXP | | 6480464 | methylmercuric chloride results in increased expression of LINC00342 mRNA | CTD | PMID:23179753 and PMID:27188386 | LINC00342 | Human | methylmercury chloride | decreases expression | EXP | | 6480464 | methylmercuric chloride results in decreased expression of LINC00342 mRNA | CTD | PMID:28001369 | LINC00342 | Human | SB 431542 | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00342 mRNA | CTD | PMID:27188386 | LINC00342 | Human | sodium arsenite | decreases expression | EXP | | 6480464 | sodium arsenite results in decreased expression of LINC00342 mRNA | CTD | PMID:34032870 | LINC00342 | Human | thimerosal | increases expression | EXP | | 6480464 | Thimerosal results in increased expression of LINC00342 mRNA | CTD | PMID:27188386 | LINC00342 | Human | toluene | increases expression | EXP | | 6480464 | Toluene results in increased expression of LINC00342 mRNA | CTD | PMID:28245982 | LINC00342 | Human | trichostatin A | increases expression | EXP | | 6480464 | trichostatin A results in increased expression of LINC00342 mRNA | CTD | PMID:26272509 | LINC00342 | Human | valproic acid | increases expression | EXP | | 6480464 | Valproic Acid results in increased expression of LINC00342 mRNA | CTD | PMID:24935251 more ... | LINC00342 | Human | valproic acid | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00342 mRNA | CTD | PMID:27188386 | |